COVID-19 Accounts For Most Of 2020’s Pharma Pipeline Growth
Novartis Still Dominates Pipeline But Roche Catches Up
Executive Summary
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.
You may also be interested in...
China Takes A Bigger Role In The World Pharma Stage
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.
COVID-19 Factor Wanes But Pharma’s R&D Pipeline Hits Record Heights
Pharma’s R&D engine has been firing on all cylinders in the past year – pipeline growth in 2021 stood at nearly twice that for the previous year, pushing the number of products under active development over 20,000 for the first time.
Quick Listen: The Story Behind The Pharmaprojects’ Pharma R&D Annual Review 2021
In this one-off podcast, hear in the inside story of how the Pharmaprojects’ Pharma R&D Annual Review 2021 is put together, its history and the trends it has revealed in R&D over the years.